Formulating poorly water soluble drugs /
Saved in:
Group Author: | ; ; |
---|---|
Published: |
Springer,
|
Publisher Address: | Cham, Switzerland : |
Publication Dates: | [2016] |
Literature type: | Book |
Language: | English |
Edition: | Second edition. |
Series: |
AAPS advances in pharmaceutical sciences series,
volume 22 |
Subjects: | |
Carrier Form: | xiv, 779 pages : illustrations (some color), forms ; 25 cm. |
Bibliography: | Includes bibliographical references and index. |
ISBN: |
9783319426075 (hardback) : 3319426079 (hardback) 9783319426099 (electronic book) 3319426095 (electronic book) |
Index Number: | RM301 |
CLC: | R914.2 |
Call Number: | R914.2/F726/2nd ed. |
Contents: |
Dedication; Preface; Contents; Contributors; Chapter 1: Route-Specific Challenges in€the€Delivery of€Poorly Water-Soluble Drugs; 1.1 Introduction; 1.2 Oral Route of€Administration; 1.2.1 Challenges in€Oral Delivery of€Poorly Water-Soluble Drugs; 1.3 Parenteral Route of€Administration; 1.3.1 Challenges in€Parenteral Delivery of€Poorly Water-ƯSoluble Drugs; 1.4 Ocular Route of€Administration; 1.4.1 Challenges in€Ocular Delivery of€Poorly Water-Soluble Drugs; 1.5 Nasal Route of€Administration; 1.5.1 Challenges in€Nasal Delivery of€Poorly Water-Soluble Drugs; 1.6 Pulmonary Route of€Administration. 1.6.1 Challenges in€Pulmonary Delivery of€Poorly Water-ƯSoluble Drugs1.7 Summary; References; Chapter 2: Optimizing the€Formulation of€Poorly Water-ƯSoluble Drugs; 2.1 Introduction; 2.1.1 Solubility Studies; 2.1.1.1 Solubility Prediction; 2.1.2 Experimental Aqueous Solubility Determination; 2.1.3 pH-Solubility Profiles; 2.1.4 Intrinsic Dissolution; 2.1.4.1 Compact Preparation; 2.1.4.2 Intrinsic Dissolution Testing; 2.2 Solid-State Characterization; 2.2.1 Thermal Analysis; 2.2.1.1 Differential Scanning Calorimetry; 2.2.1.2 Flory-Huggins; 2.2.1.3 Thermogravimetric Analysis. 2.2.2 Fourier Transform Infrared Spectroscopy2.2.2.1 Sample Preparation; 2.2.2.2 Polymorph Screening; 2.2.2.3 Excipient Interactions; 2.2.3 X-Ray Diffraction; 2.2.3.1 Parameter Selection; 2.2.3.2 Polymorph Screening; 2.2.3.3 Excipient Interactions; 2.2.3.4 Pair Distribution Function (PDF); 2.2.4 Specific Surface Area; 2.2.4.1 BET Surface Area Analysis; 2.2.5 Solid-State Nuclear Magnetic Resonance (SSNMR); 2.2.6 Residual Solvent Analysis; 2.2.6.1 Residual Solvent Guidelines; 2.2.6.2 Analytical Determination of€Residual Solvent Levels; 2.3 Stability Testing; 2.3.1 Stability Monitoring. 2.3.2 Chemical Stability2.3.3 Stability Testing Conditions; 2.4 Dissolution Testing; 2.4.1 Dissolution Studies; 2.4.1.1 Sample Handling; 2.4.1.2 Excipient Screening for€Supersaturation Maintenance Ability; 2.4.1.3 Supersaturation Dissolution Studies; 2.4.1.4 Alternative Dissolution Studies; 2.4.2 In Vivo Testing; 2.4.2.1 Administration Via Inhalation; 2.4.2.2 Oral Administration; 2.5 Conclusions; References; Chapter 3: Solid-State Techniques for€Improving Solubility; 3.1 Introduction; 3.2 Pharmaceutical Salts; 3.2.1 Pharmaceutical Salt Selection; 3.2.2 Solubility Enhancement. 3.3 Polymorphs and€Amorphous Forms3.3.1 Polymorph Preparation; 3.3.2 Amorphous Form Preparation; 3.3.3 Thermodynamics of€Metastable Solids; 3.3.4 Solubility and€Bioavailability Enhancement; 3.4 Pharmaceutical Co-crystals; 3.4.1 Co-crystal Preparation; 3.4.2 Solubility of€Co-crystals; 3.5 Summary; References; Chapter 4: Mechanical Particle-Size Reduction Techniques; 4.1 Introduction; 4.2 Rationale Behind the€Reduction of€Particle-Size; 4.3 Milling; 4.3.1 Dry Milling; 4.3.1.1 Fluidized Bed Jet Milling; 4.3.1.2 Spiral Jet "Pancake" Mill; 4.3.1.3 Pin Mill. |